Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis

Table 2 Cost-effectiveness analyses

	Costs	ΔCosts	QALYs	ΔQALYs	ICER
6-month time horizon
DOACs	654.65	− 1064.66	0.40	0.03	−32,922.16
LMWHs	1719.31		0.37
5-year time horizon
DOACs	1447.22	− 1927.48	3.07	−0.02	112,895.50
LMWHs	3374.70		3.09
Subgroup	0.28
DOACs	657.85	− 1058.71	0.40	0.03	−32,821.83
LMWHs	1716.56		0.37

DOACs Direct oral anticoagulants, LMWHs Low molecular weight heparins, ICER Incremental cost-effectiveness ratio, QALYs Quality adjusted life-years

ISSN: 1477-9560